Related Experiment Video

Updated: May 20, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Haplotype-based case-control study of CYP4A11 gene and myocardial infarction

Zhenyan Fu1, Tomohiro Nakayama, Naoyuki Sato

  • 1Division of Laboratory Medicine, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.

Hereditas
|July 19, 2012
PubMed

Insights

The CYP4A11 gene T-T-A haplotype may protect Japanese men against myocardial infarction (MI). This genetic marker was found at lower frequencies in male MI patients compared to controls.

Area of Science:

  • Genetics
  • Cardiovascular Disease Research
  • Metabolism

Background:

  • Cytochrome P450 family member CYP4A11 converts arachidonic acid to 20-HETE, a key metabolite for cardiovascular health.
  • Genetic variations in CYP genes are increasingly linked to myocardial infarction (MI) risk.
  • Understanding genetic associations is crucial for personalized cardiovascular disease prevention strategies.

Purpose of the Study:

  • To investigate the association between the human CYP4A11 gene and myocardial infarction (MI).
  • To analyze gender-specific differences in the CYP4A11 gene's association with MI.
  • To identify potential genetic markers for MI risk in the Japanese population.

Main Methods:

  • A haplotype-based case-control study was conducted.
  • 239 MI patients and 285 controls were genotyped for three CYP4A11 single-nucleotide polymorphisms (SNPs): rs2269231, rs1126742, and rs9333025.
  • Data were analyzed for total subjects, men, and women separately.

Main Results:

  • No significant differences in genotype or allele distributions of the three SNPs were observed between MI patients and controls across all groups.
  • Haplotype analysis revealed a significant difference in overall haplotype distribution between MI patients and controls in the total and male groups (P < 0.001).
  • The T-T-A haplotype (comprising rs2269231, rs1126742, rs9333025) was significantly less frequent in male MI patients than in male controls (P < 0.001), suggesting a protective effect.

Conclusions:

  • The T-T-A haplotype of the CYP4A11 gene appears to be a protective genetic marker against myocardial infarction in Japanese men.
  • Further research is warranted to elucidate the functional mechanisms underlying this protective association.
  • These findings contribute to understanding the genetic underpinnings of cardiovascular disease and may inform future risk stratification approaches.

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...